Béatrice Vallée
17
Documents
Publications
- 2
- 2
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 17
- 16
- 16
- 13
- 10
- 9
- 9
- 9
- 8
- 8
- 7
- 6
- 4
- 4
- 3
- 3
- 3
- 3
- 3
- 3
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
|
Tetrahydropyridine LIMK inhibitors: Structure activity studies and biological characterizationEuropean Journal of Medicinal Chemistry, 2024, 271, pp.116391-116391. ⟨10.1016/j.ejmech.2024.116391⟩
Article dans une revue
hal-04575964v1
|
|
LIM kinases, promising but reluctant therapeutic targets: chemistry and preclinical validation in vivoCells, 2022, 11 (13), pp.2090. ⟨10.3390/cells11132090⟩
Article dans une revue
hal-03721458v1
|
|
Synthesis of Heterospirocycles through Gold‐(I) Catalysis, Useful Building Blocks for Medicinal ChemistryAdvanced Synthesis and Catalysis, 2021, ⟨10.1002/adsc.202101080⟩
Article dans une revue
hal-03411162v1
|
4-(7H-Pyrrolo[2,3-D]pyrimidin-4-yl)-3,6-dihydropyridine-(2H)-carboxamide derivatives as Limk and/or Rock kinases inhibitors for use in the treatment of cancerFrance, Patent n° : WO2021239727 A1. BCT. 2021
Brevet
hal-03555349v1
|